Zentalis Pharmaceuticals Inc Ordinary Shares ZNTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
-
Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies
-
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
-
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
-
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
-
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 168
- Website
- https://www.zentalis.com
Comparables
Valuation
|
Metric
|
ZNTL
|
CGON
|
MGNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.63 | 4.42 | 3.89 |
Price/Sales | 5.89 | 244.06 | 5.66 |
Price/Cash Flow | — | — | — |
Price/Earnings
ZNTL
CGON
MGNX
Financial Strength
|
Metric
|
ZNTL
|
CGON
|
MGNX
|
|---|---|---|---|
Quick Ratio | 0.00 | 46.66 | 2.53 |
Current Ratio | 6.59 | 47.57 | 2.71 |
Interest Coverage | — | — | −128.87 |
Quick Ratio
ZNTL
CGON
MGNX
Profitability
|
Metric
|
ZNTL
|
CGON
|
MGNX
|
|---|---|---|---|
Return on Assets (Normalized) | −27.12% | −15.24% | −59.21% |
Return on Equity (Normalized) | −33.35% | −26.61% | −120.96% |
Return on Invested Capital (Normalized) | −36.67% | −25.60% | −102.88% |
Return on Assets
ZNTL
CGON
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ylqpqkjtv | Dtq | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zxcxznvsv | Kcynqv | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vdrjphs | Ddrrcbn | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zycsxrrh | Dwgjxy | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Xymqszvmw | Xygm | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Lzzwmvhj | Gnfd | $29.2 Bil | |||
| Moderna Inc
MRNA
| Djrrxpf | Wmhxh | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jkvndlj | Klhxy | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ylzqtcqb | Drxhxc | $13.2 Bil | |||
| Incyte Corp
INCY
| Sjnnrhq | Dqzqys | $13.0 Bil |
United States